Randomized, multicenter trial to evaluate the cost-effectiveness of 2 different follows up programs in head and neck cancer survivors. Patients in complete remission at month 6 (+/- 1 month) after curative treatment will be randomized in two arms according to 2 different follow up approaches: Non Intensive Follow up approach (Arm A) with no radiologic evaltuations scheduled, but required only at the occurence of any signs or symptoms and Intensive Follow up approach (Arm B) with scheduled radiologic evaluations.
The choice about timing of follow visits for each patient will be performed before randomization and will be tailored to the single patient in accordance to NCCN and AIOCC guidelines following this scheduling: * Oral Cavity cancer: every 2 months for the 1st year, every 3 months in the 2nd year, every 4 months in the 3rd year and every 6 months in the 4th and 5th year * Oropharyngeal and laryngeal cancer: every 3 months for the 1st and the 2nd year, every 4 months in the 3rd year and every 6 months in the 4th and 5th year * Hypopharyngeal cancer: every 3 months for the 1st and the 2nd year, every 6 months from the 3rd to the 5th year Patients deemed to be in complete remission at month 6 (+/- 1 month) after curative treatment will be randomized in two follow up arms: ARM A (Non intensive): follow up according to NCCN guidelines, consisting of outpatient visits according to the schedule foreseen for single head and neck subsite. At each follow up visit the patients will report all new symptoms and they will receive both physical and fiberoptic endoscopic head and neck examination. Laboratory tests (complete blood count, renal, hepatic and thyroid function) will be performed once a year. Quality of life questionnaire (EuroQol 5D5L, EORTC QLQ C-30 and HN35) will be administered to patients every other visit for the first 2 years and then at each visit. During each visit, a socio-economic questionnaire will be also administered. Locoregional imaging will be performed within 6 months after treatment end and then will be recommended only on the occurrence of new signs or symptoms. Only patients in this arm will be contacted by a phone call between visits in order to monitor patient's reported symptoms which could be potentially related to disease recurrence. ARM B (Intensive): follow up outpatient visits will be performed similarly to ARM A, including physical and fiberoptic endoscopic head and neck evaluation and laboratory tests and questionnaires. Locoregional imaging will be requested for all the patients 2 times/year in the first 2 years and 1 time/year in the third and fourth year; PET scan will be requested yearly in the first 3 years. In the first year after RT end, MRI or CT scan will be performed at screening and at sixth month after enrollment, while PET scan will be performed six months after enrollment. Radiological imaging with PET will be customized according to smoking history being performed in subjects \>50 years and with a smoking history of \> 20 pack/years. Randomization will be stratified according to site of primary disease, smoking history (\> 10pack years) and likelihood of feasibility or non feasibility of salvage surgery if a recurrence at T/N level would emerge (salvage surgery feasibility).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Enrollment
330
Scheduled radiologic evaluations (CT or MRI scan) and PET scan in the case that patiets are ≥ 50 years old and with a smokink history ≥ 20 pack year
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Milan, MI, Italy
Policlino S. Orsola-Maplighi
Bologna, Italy
Spedali Civili di Brescia
Brescia, Italy
Azienda Ospedaliera Universitaria Careggi
Florence, Italy
Istituto Nazionale per la ricerca sul cancro
Genova, Italy
Istituto Europeo di Oncologia
Milan, Italy
Policlinico di Modena
Modena, Italy
Istituto Nazionale Tumori IRCCS - Fondazione Pascale
Naples, Italy
Ospedale di Parma
Parma, Italy
Fondazione IRCCS Policlinico San Matteo
Pavia, Italy
...and 5 more locations
Evaluation of the most cost-effective follow up strategy
To evaluate the most cost-effective follow up strategy by comparing health consequences and costs of the two alternative follow-up strategies.
Time frame: 3 years
Evaluation of the percentage of potentially salvageable recurrences or second primaries
To evaluate the percentage of potentially salvageable recurrences or second primaries in both groups of follow up approach.
Time frame: 3 years
Assessment of the cause-specific survival
To assess the cause-specific survival (CSS).
Time frame: 3 years
Assessment of the OS of patients recurring
To assess the overall survival (OS) of patients recurring in both groups of follow up approach.
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.